Screener
Acadia Pharmaceuticals ACAD Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net cash provided by (used in) investing activities | 57,752 | (167,343) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | 14,725 | 17,794 |
| Net cash provided by financing activities | 14,725 | 17,794 |
| Effect of exchange rate changes on cash | 52 | 19 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 207,291 | (65,251) |
| Cash, cash equivalents and restricted cash | ||
| Beginning of period | 185,540 | 328,359 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's financing cash flow?
- Acadia Pharmaceuticals (ACAD) reported financing cash flow of $10.49M in Q2 2026.
- How has Acadia Pharmaceuticals's financing cash flow changed year-over-year?
- Acadia Pharmaceuticals's financing cash flow decreased by 34.2% year-over-year, from $15.96M to $10.49M.
- What is the long-term trend for Acadia Pharmaceuticals's financing cash flow?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's financing cash flow has grown at a 28.7% compound annual growth rate (CAGR), from $18.16M to $49.88M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Acadia Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude